Korean Market
OWNR
Hanmi Science
★

Major Shareholder Song Yeong-suk Reports Change in Stock Pledge Agreement… Stake Unchanged at 63.89%, No Change in Control

 
EXCH
Hanmi Science
★

Hanmi Science Sets Minimum 30% Total Shareholder Return Target by 2030... Accelerating Shareholder Value via Dividends, Buybacks, and RSUs

 
EXCH
Hanmi Science
★★★★

Hanmi Science Subsidiary Hanmi Pharmaceutical Signs $1.26B GLP2 Technology Transfer Agreement with Eli Lilly - Significant Share Price Catalyst and Enterprise Value Upside

 
EXCH
Hanmi Science
★

Hanmi Pharm's Hypertension Drug HCP1803-4 Gets Phase 3 Approval... Pipeline Value Expected to Rise, but 10% Success Rate Risk Remains

 
EXCH
Hanmi Science
★

Hanmi Pharm Signs 52.7 Billion KRW, 10-Year Supply Contract with Organon for 3 CV/Respiratory Drugs

 
PERI
Hanmi Science
★★★

Hanmi Science Reports 24% Operating Profit Growth in Q1 2026 and Strengthens Shareholder Returns

 
EXCH
Hanmi Science
★★★

Hanmi Science Q1 2026: Net profit +73% YoY, Operating profit +24% YoY